Clinical Trials Browser

Interventional × danvatirsen × Clear all

NCT03819465 2026-05-12

MAGELLAN

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02499328 2026-02-11

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Phase 1/2 Completed

340 enrolled 53 charts

Head & NeckOther solid neoplasm

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05814666 2026-01-30

PEMDA-HN

Phase 2 Terminated

69 enrolled 21 charts

Squamous Cell Carcinoma of Head and Neck

NCT02546661 2025-12-29

BISCAY

Phase 1 Active not recruiting

Muscle Invasive Bladder Cancer

NCT05986240 2025-11-10

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT02983578 2025-05-06

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Phase 2 Active not recruiting

GastrointestinalThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03421353 2024-08-21

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumours

NCT03527147 2022-08-15

PRISM

Phase 1 Completed

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03794544 2022-02-24

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Phase 2 Completed

84 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03394144 2019-06-24

Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

Phase 1 Completed

Advanced Solid Malignancies

NCT02549651 2019-02-27

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Phase 1 Completed

Lymphoma, Large B-Cell, Diffuse

NCT02417753 2017-05-15

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

Phase 2 Terminated

1 enrolled 10 charts

GastrointestinalGynecologic

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

NCT01839604 2017-03-06

A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma

Phase 1 Completed

58 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular